Pharmaceuticals

Increasing breast cancer cases are boosting the Enhertu Market 2026

March 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Enhertu Market During The Forecast Period 2026–2030?

Historically, growth was propelled by the expanding incidence of HER2 positive cancers, alongside the inherent limitations of conventional chemotherapy. This progression was further bolstered by the initial achievements of targeted therapies, advancements in molecular diagnostics, and an uptick in oncology drug approvals.

Anticipated growth in the forecast period is fueled by several factors, including the widening indications for antibody drug conjugates, a rise in HER2 testing adoption, and increasing demand for precision cancer therapies. This expansion is further supported by robust funding for oncology research and positive clinical trial outcomes.

Key trends observed during the forecast period involve the prevalence of antibody drug conjugate cancer therapies and specific HER2-directed treatments. Other notable trends include the broadening scope of precision oncology, the growing utilization of biomarker-based cancer care, and a noticeable shift towards advanced-line targeted therapies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20057&type=smp

What Underlying Factors Are Accelerating The Growth Of The Enhertu Market?

The rising occurrence of breast cancer is projected to fuel the expansion of the enhertu market in the future. Breast cancer is a malignancy that originates in the breast cells, frequently in the milk ducts or lobules, and possesses the capacity to spread to other areas of the body. The escalating frequency of breast cancer can be attributed to several contributing elements, such as an aging demographic, inherited predispositions, lifestyle choices like inadequate nutrition and insufficient physical activity, environmental exposures, and advancements in detection and screening methodologies. Enhertu offers a targeted therapeutic approach for individuals with breast cancer by delivering a powerful blend of chemotherapy and HER2-targeted treatment, thereby contributing to better results for those with advanced or metastatic HER2-positive breast cancer. As an illustration, in September 2023, Breast Cancer Now, a UK-based breast cancer charity, reported that roughly 600,000 individuals in the UK are currently living post-breast cancer diagnosis, a figure anticipated to reach 1.2 million by 2030. Consequently, the growing incidence of breast cancer is a key driver for the enhertu market.

What Market Segments Are Evaluated Within The Enhertu Market?

The enhertu market covered in this report is segmented –

1) By Indication: HER2-Positive Metastatic Breast Cancer, HER2-Low Metastatic Breast Cancer, HER2-Mutant Non-Small Cell Lung Cancer (NSCLC), HER2-Positive Metastatic Gastric Cancer

2) By Treatment Line: First-Line Therapy, Second-Line Therapy, Third-Line Therapy

3) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies

What Industry Trends Are Redefining The Enhertu Market?

A primary development in the Enhertu market centers on conducting clinical trials aimed at expanding its approved uses to include various cancers, such as non-small cell lung cancer (NSCLC) and colorectal cancer, beyond its current application in HER2-positive breast cancer. These trials are crucial for establishing Enhertu as a targeted therapy, exhibiting notable statistical and clinical improvements in progression-free survival for HR-positive, HER2-low metastatic breast cancer patients in the DESTINY-Breast06 Phase 3 study, following at least one line of endocrine therapy. As an illustration, Daiichi Sankyo, a Japan-based pharmaceutical firm, and AstraZeneca plc, a UK-based pharmaceutical firm, publicly shared the outcomes of the DESTINY-Breast06 Phase 3 trial for ENHERTU (trastuzumab deruxtecan) in April 2024. The findings confirmed ENHERTU’s substantial improvement in progression-free survival (PFS) for patients with hormone receptor (HR)-positive, HER2-low metastatic breast cancer who had previously undergone one or more lines of endocrine therapy. This particular study holds significance as it marks the initial instance where a HER2-directed treatment has demonstrated a clinically valuable advantage for this distinct group of patients.

Who Are The Top Market Participants Influencing The Enhertu Market?

Major companies operating in the enhertu market are AstraZeneca Plc, Daiichi Sankyo Co. Ltd.

Read the full enhertu market report here:

https://www.thebusinessresearchcompany.com/report/enhertu-global-market-report

Which Region Is Projected To Dominate The Enhertu Market During The Forecast Period?

North America was the largest region in the enhertu market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the enhertu market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Enhertu Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20057&type=smp

Browse Through More Reports Similar to the Global Enhertu Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Trade Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/trade-finance-global-market-report

Inductor Market Market Report 2026

https://www.thebusinessresearchcompany.com/report/inductor-market-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795